Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom

Blood

Volumn 117, Issue 23, 2011, Pages 6367-6370

  Hay, Charles R M ^a   Palmer, Ben ^b   Chalmers, Elizabeth ^c   Liesner, Ri ^d   MacLean, Rhona ^e   Rangarajan, Savita ^f   Williams, Michael ^g   Collins, Peter W ^h  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b United Kingdom National Haemophilia Database   (United Kingdom)

^c ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^d GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^e ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^f ST THOMAS HOSPITAL   (United Kingdom)

^g BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^h UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTIBODY TITER; ARTICLE; CHILD; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; DISEASE SEVERITY; FOLLOW UP; HEMOPHILIA A; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SEROLOGY; SEVERE HEMOPHILIA A; UNITED KINGDOM;

EID: 79959486802     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-09-308668     Document Type: Article

References (15)

1. Astermark J. Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors. Haemophilia. 2006;12(suppl 6):8-13.
2. Gouw SC, van den Berg HM. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment. Semin Thromb Haemost. 2009;35(8):723-734.
3. Gouw SC, van der Bom JG, M van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood. 2007; 109:4648-4654. (Pubitemid 46827754)
4. McMillan CW, Shapiro SS, Whitehurst D, et al. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study, II: observations on the initial development of factor VIII:C inhibitors. Blood. 1988;71:344-348. (Pubitemid 18089520)
5. White GC, DiMichele DM, Mertens K et al. Utilisation of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates: recommendations of the Scientific Subcommittee on factor VIII and factor IX of the Scientific Standardisation Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1999;81(3): 462.
6. Kempton CL, Soucie JM, Abshire TC. Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates. J Thromb Haemost. 2006;4:2476-2481.
7. Giles AR, Rivard GE, Teitel J, Walker I. Surveillance for factor VIII inhibitor development in the Canadian hemophilia A population following widespread introduction of recombinant factor VIII replacement therapy. Transfus Sci. 1998;19(2):139-148.
8. Rubinger M, Lillicrap D, Rivard GE, et al. A prospective surveillance study of factor VIII inhibitor development in the Canadian hemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose. Haemophilia. 2008;14(2):281-286. (Pubitemid 351338688)
9. White GC, Courter S, Bray GL, Gomperts ED. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A: the Recombinate Previously Treated Patient Study Group. Thromb Haemost. 1997;77(4):660-667. (Pubitemid 27182960)
10. Recht M, Nemes L, Malysaiac M, et al. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy and pharmacokinetic equivalence to full length recombinant factor VIII. Haemophilia. 2009;15(4):869-880.
11. Lee ML, Roth DA. A Bayesian approach to the assessment of inhibitor risk in studies of factor VIII concentrates. Haemophilia. 2005;11(1):5-12. (Pubitemid 40253761)
12. Sultan Y. Prevalence of inhibitors in a population of 3435 hemophilia patients in France: French Hemophilia Study Group. Thromb Haemost. 1992;67(6):600-602.
13. Darby SC, Kan SW, Spooner RJ, et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood. 2007; 110:815-825. (Pubitemid 47267416)
14. Hay CRM, Ludlam CA, Colvin BT, Hill FGH, et al. Factor VIII inhibitors in mild and moderate severity haemophilia A. Thromb Haemost. 1998;79(4): 762-766. (Pubitemid 28163851)
15. Scharrer I, Ehrlich HJ. Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII. Haemophilia. 2001;7:346-348. (Pubitemid 32677651)